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Background: Adrenocortical carcinoma is a rare and aggressive malignancy. Patients usually present early with
manifestation of abnormal hormone secretion. However, adrenocortical carcinoma can also be nonfunctioning, and
such patients present late with a mass effect or distant metastases.
Case presentation: We herein report a case of a 30-year-old Sri-Lankan woman who presented with a 3-month
history of left flank pain associated with nausea, vomiting, and weight loss. Imaging revealed a large left upper
quadrant mass with a 1.8-cm left lung nodule. The differential diagnoses included a left adrenal mass, left upper pole
renal mass, and retroperitoneal sarcoma. A functional adrenal work-up revealed no abnormal findings. Surgical excision
of the mass was uneventful with no postoperative complications. Pathological analysis revealed a nonfunctioning
adrenocortical carcinoma measuring 16 × 14 × 10 cm. To our knowledge, a mass of this size is among the largest
nonfunctioning adrenocortical carcinomas reported in the published literature. The investigations and approach to
treatment were consistent with those in the published literature.
Conclusion: Large nonfunctioning adrenocortical carcinomas pose a diagnostic and therapeutic challenge, and most
are diagnosed at a late stage. Appropriate imaging and functional work-up of the mass are vital before treatment.
Surgical excision is safe, even for large adrenocortical carcinomas; excision in patients with advanced disease has been
shown to have the best outcomes.
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Adrenocortical carcinoma (ACC) is a rare and aggressive
malignancy with an estimated annual incidence of one
to two cases per million inhabitants in the United States
[1,2]. The age distribution is bimodal, with peaks occur-
ring at 5 to 20 and 40 to 50 years of age [1-3]. A slight
female predominance has been shown [1].
Adrenal masses can be broadly divided into hyper-
functioning (hormone-secreting) and nonfunctioning (non-
hormone-secreting). Functioning ACC presents earlier with
hormonal manifestations such as virilization, feminization,
or Cushing’s syndrome. However, nonfunctioning tumors
pose a diagnostic challenge because they are diagnosed inci-
dentally due to a mass effect or metastatic disease. More-
over, successful radical management is seldom achievable
because most diagnoses are made when the tumor has* Correspondence: saad.aldousari@gmail.com
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article, unless otherwise stated.either invaded local structures or metastasized, explaining
the poor prognosis associated with these masses [2,3].
Even after a grossly complete resection, most patients
develop early tumor recurrence or distant metastasis [2].
This is presumed to be due to occult micrometastases
that were not detected at the time of diagnosis [4,5]. The
5-year overall survival rate ranges from 16% to 44% [6].
However, a more recent case series suggested an improved
5-year overall survival rate reaching 60%; in this study,
34% of the enrolled patients had metastatic disease at
diagnosis [6]. Early-stage disease in the absence of lymph
node and distant metastases and an age of <40 years have
been shown to be positive prognostic factors [7,8]. Add-
itionally, negative resection margins have been shown to
improve survival independent of other factors [9].
The most frequent metastatic sites are the lung, lymph
nodes, liver, bone, and inferior vena cava at 71%, 68%,
42%, 26%, and 20%, respectively [10]. We herein present
a case of a giant nonfunctioning ACC with local tumor
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A 30-year-old Sri-Lankan woman presented with left flank
pain. The pain was intermittent, sharp, and of moderate se-
verity and radiated to the groin. The patient reported no
history of lower urinary tract symptoms or gross hematuria.
The pain was associated with weight loss of 8 kg over a
period of 3 months. Her medical and surgical history
was not significant, and the patient was not on any
regular medications.
The patient was afebrile on presentation with no micro-
scopic hematuria. On physical examination, the abdomen
was soft with minimal tenderness over the left flank, and a
palpable left upper quadrant mass was present. The rest of
the clinical examination revealed normal findings.
A computed tomography (CT) scan showed a large left
upper quadrant mass measuring 17 × 13 × 12 cm in its
greatest dimension. The mass crossed the midline and
compressed the stomach, spleen, pancreas, and smallFigure 1 A coronal section of the abdomen and pelvis illustrating the
the adjacent structures and occupying the whole left upper quadrant.bowel (Figures 1 and 2). The origin of the mass was un-
clear, and the differential diagnoses included a left adrenal
mass, left upper pole renal mass, and retroperitoneal sar-
coma. A functional adrenal work-up was performed ac-
cording to the Canadian Urological Association guidelines
and included measurement of serum aldosterone, potas-
sium, renin, and adrenocorticotrophic hormone levels; a
dexamethasone suppression test; and measurement of 24-
hour urinary metanephrine levels. All results were within
the reference ranges.
The metastatic work-up included CT scans of the head
and chest and a bone scan. The head CT scan revealed
normal findings. The chest CT scan showed a 1.8-cm nod-
ule in the medial left lower lobe, close to the posterior
mediastinum, as well as two subcentimetric nodules in the
left lung. Neither the bone scan nor magnetic resonance
imaging (MRI) showed evidence of bone metastasis. A de-
cision was made to proceed with en bloc excision of thesize of the mass. The mass is shown compressing and displacing
Figure 2 A cross section of the abdomen showing the large mass crossing the midline.
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the suspicious lung nodules, and they planned to biopsy
the lung lesion after excision of the primary tumor.
Operative findings
A Chevron incision was made, and a Gomez poly tract
retractor (Pilling®) was used to ensure adequate expos-
ure. The mass was exposed after medial reflection of the
descending colon and was found to be displacing the
stomach, pancreas, and spleen, but it had a grossly nega-
tive margin with no evidence of adjacent organ invasion.
The mass was covering the left renal hilum and was
densely adhered to the aorta. After adequate exposure of
the left kidney, the mass was noted to be densely ad-
hered to the upper pole with no surgically defined plane.
It seemed to be arising from the upper pole of the left
kidney. In the presence of a vascular surgeon, the mass
was dissected and the left renal hilum was carefully iso-
lated. We decided intraoperatively to proceed with left
radical nephrectomy. This decision was made to avoid
positive surgical margins if partial nephrectomy was per-
formed given the wide base of tumor adherence to the
kidney. Upon vascular control of the left renal artery
and vein, the mass significantly shrunk in size and be-
came less congested. It was then easily dissected off the
aorta. No enlarged lymph nodes were identified. After
ensuring adequate hemostasis, Surgicel® Fibrillar™ was
applied, and an intra-abdominal drain was inserted.The postoperative recovery was uneventful. The drain
was removed on postoperative day 2, and the patient
was discharged on postoperative day 6. She was followed
up 4 weeks postoperatively with no complications. After
returning to her home country, her local cardiothoracic
surgeon obtained biopsy specimens from the lung nod-
ules; these were found to be benign granulomas. How-
ever, contrast-enhanced CT of the chest, abdomen, and
pelvis performed 3 months postoperatively showed new
liver metastasis.
Histological findings
Histological examination showed a 1.63-kg en bloc left rad-
ical nephrectomy specimen that measured 20.0- × 16.5- ×
11.0-cm (Figure 3a and b). Opening of the specimen re-
vealed a huge mass arising from the left adrenal gland
measuring 16 × 14 × 10 cm. The tumor was tan-yellow and
well demarcated, and it showed a clear line of cleavage
from the left kidney. Histological examination of the tumor
showed overt features of malignancy including a high nu-
clear grade, high mitotic activity (>10/50 high-power fields),
and foci of diffuse growth admixed with single infiltrating
cells. Venous and capsular invasion was also present. Im-
munohistochemistry revealed positive staining of tumor
cells for synaptophysin and inhibin, supporting a diagnosis
of ACC (Figure 4a–c). The margins were uninvolved by the
tumor. In accordance with the 2010 Tumor Nodes Metas-
tasis staging system, the tumor stage was pT3NxMx.
Figure 3 Illustrates the extracted mass which includes the kidney and the adrenal gland. a) Gross appearance of the specimen showing a
well-encapsulated mass with a distinct plane separating it from the kidney. b) En bloc specimen including the left kidney.
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Approximately 60% of patients with ACC present with
symptoms and signs of hormonal secretion. This was not a
feature in the present case. Hormone secretion is not adiscriminating feature between benign and malignant adre-
nocortical masses. The silent clinical nature of nonfunc-
tioning ACC results in poorer outcomes. Hence, the
majority of patients with nonfunctioning ACC present with
Figure 4 Illustrates the histopathological and immuno-cytochemistry stained slides as described in a, b and c. a) Hematoxylin and
eosin stain of the adrenal gland. Right: Tumor. Left: Residual rim of normal adrenal gland (10×). b) Immunohistochemical stain: inhibin (10×).
c) Immunohistochemical stain: vimentin (10×).
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for adrenal masses must include determination of whether
the mass is functioning or nonfunctioning and whether itis benign or malignant. Hormonal evaluation helps define
the functional status of the tumor and can also help define
its origin. Radiographic studies in the form of CT or MRI
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ses. Emerging evidence suggests that fluorodeoxyglucose-
fused positron emission tomography with CT (FDG-PET/
CT) is superior to CT alone [11]. However, FDG-PET/CT
is still considered a complimentary study and is not recom-
mended for ACC work-up [11].
With the presence of a questionable metastatic pul-
monary nodule and large tumor of >4 cm, the clinical
suspicion of malignancy was high in this case and fa-
vored radical adrenalectomy [12-14]. To the best of our
knowledge, a mass of this size is among the largest non-
functioning ACCs reported in the literature [15,16].
Despite the poor prognosis in this patient group,
chemotherapy has a limited role in the treatment of ACC,
and surgical resection has been shown to have the best
outcomes [7,8]. However, recent studies have shown a role
for adjuvant chemotherapy in prolonging recurrence-free
and overall survival [5,8,9]. There is no established dur-
ation of adjuvant chemotherapy. High-risk patients are
currently being treated for 5 years with mitotane. In pa-
tients with proven lung metastasis, the published evidence
suggests that en bloc excision of involved organs and pul-
monary metastasectomy could improve overall survival
[5,8]. Postoperative surveillance for recurrence should be
performed every 3 months for the first 2 years and then
every 6 months for 5 years. Contrast-enhanced CT scans
of the chest, abdomen, and pelvis are the standard of care
for follow-up; however, FDG-PET/CT scans are used in
some specialized centers and are still under investigation
[11]. We have herein illustrated the successful and safe
surgical resection of a large ACC with no postoperative
complications. We will provide an update on the condi-
tion and survival of the patient when available.
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